Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis

被引:228
作者
Astier, Anne L.
Meiffren, Gregory
Freeman, Samuel
Hafler, David A.
机构
[1] Brigham & Womens Hosp, Lab Mol Immunol, Ctr Neurol Dis, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
[3] INSERM, U503, Lab Fundamental & Clin Immunobiol, F-69008 Lyon, France
关键词
D O I
10.1172/JCI29251
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Loss of Treg function appears to be a critical factor in the pathogenesis of human autoimmune diseases. Attention has focused on defects of CD4(+)CD25(high) Tregs, and techniques have been developed to determine their function. In contrast, the role of Tr1 regulatory T cells, which secrete the antiinflammatory cytokine IL-10, in autoimmune disease has not been well assessed. CD46 is a newly defined costimulatory molecule for T cell activation, and CD46-costimulated human T cells induce a Tr1 Treg phenotype with considerable amounts of IL-10 secretion. Here, we examined the role ofTr1 cells in patients with multiple sclerosis (MS) by stimulating CD4(+) T cells with anti-CD3 and -CD46 mAbs and measuring IL-10 secretion. There were striking defects in the induction ofTrl cells with CD46 costimulation as measured by IL-10 but not IFN-gamma secretion in patients with MS compared with healthy subjects. This loss ofTrl cell-associated IL-10 secretion was specific to CD46 and not CD28 costimulation and was associated with an altered regulation of the CD46-Cy2 isoform that differentially regulates T cell function in a CD46-transgenic murine model. These data demonstrate a second major Treg defect in human autoimmune disease associated with the CD46 pathway.
引用
收藏
页码:3252 / 3257
页数:6
相关论文
共 48 条
[1]   Immunotherapeutic approaches in multiple sclerosis [J].
Adorini, L .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2004, 223 (01) :13-24
[2]   ACTIVATED SUPPRESSOR-CELL FUNCTION IN SEVERELY DISABLED PATIENTS WITH MULTIPLE-SCLEROSIS [J].
ANTEL, JP ;
FREEDMAN, MS ;
BRODOVSKY, S ;
FRANCIS, GS ;
DUQUETTE, P .
ANNALS OF NEUROLOGY, 1989, 25 (02) :204-207
[3]   CD46, a new costimulatory molecule for T cells, that induces p120CBL and LAT phosphorylation [J].
Astier, A ;
Trescol-Biémont, MC ;
Azocar, O ;
Lamouille, B ;
Rabourdin-Combe, C .
JOURNAL OF IMMUNOLOGY, 2000, 164 (12) :6091-6095
[4]   CD4+ regulatory T cells:: Mechanisms of induction and effector function [J].
Bacchetta, R ;
Gregori, S ;
Roncarolo, MG .
AUTOIMMUNITY REVIEWS, 2005, 4 (08) :491-496
[5]   Non-Th2 regulatory T-cell control of Th1 autoimmunity [J].
Bach, JF .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2001, 54 (1-2) :21-29
[6]  
Baecher-Allan CM, 2005, CLIN IMMUNOL, V117, P192, DOI 10.1016/j.clim.2005.08.008
[7]   Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4(+) T cells via CD40 ligand [J].
Balashov, KE ;
Smith, DR ;
Khoury, SJ ;
Hafler, DA ;
Weiner, HL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (02) :599-603
[8]   Tr1 cells: From discovery to their clinical application [J].
Battaglia, M ;
Gregori, S ;
Bacchetta, R ;
Roncarolo, MG .
SEMINARS IN IMMUNOLOGY, 2006, 18 (02) :120-127
[9]  
Bettelli E, 1998, J IMMUNOL, V161, P3299
[10]   How do CD4+CD25+ regulatory T cells control autoimmunity? [J].
Bluestone, JA ;
Tang, QZ .
CURRENT OPINION IN IMMUNOLOGY, 2005, 17 (06) :638-642